The biology of multiple myeloma

Journal of Cancer Research and Clinical Oncology

Volumn 126, Issue 8, 2000, Pages 441-447

  Drach, Johannes ^a   Kaufmann, Hannes ^a   Urbauer, Eleonora ^a   Schreiber, Susanne ^a   Ackermann, Jutta ^a   Huber, Heinz ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Angiogenesis; B lymphocytes; Cytogenetics; Cytokines; Multiple myeloma; Oncogenes

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN HEAVY CHAIN;

B LYMPHOCYTE; BONE MARROW; CELL DIFFERENTIATION; CELL SURVIVAL; CHROMOSOME 13Q; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION 14; CYTOGENETICS; GENETIC HETEROGENEITY; GERMINAL CENTER; MULTIPLE MYELOMA; NEOVASCULARIZATION (PATHOLOGY); ONCOGENE; PLASMA CELL; PRIORITY JOURNAL; REVIEW; STROMA CELL; TUMOR SUPPRESSOR GENE;

EID: 0033928972     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004320050011     Document Type: Review

References (64)

1. Aman MJ, Rudolf G, Goldschmitt J, Aulitzky WE, Lam C, Huber C, Peschel C (1993) Type-1 interferons are potent inhibitors of interleukin-8 production in hematopoietic and bone marrow stromal cells. Blood 82: 2371-2378
2. Avet-Loiseau H, Li JY, Morineau N, Facon T, Brigaudeau C, Harousseau JL, Grosbois B, Bataille R (1999) Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Blood 94: 2583-2589
3. Bakkus MHC, Heirman C, Van-Riet I, Van-Camp B, Thielemans K (1992) Evidence that multiple myeloma Ig heavy-chain VDJ-genes show somatic mutations but show no intraclonal variation. Blood 80: 2326-2335
4. Bakkus MHC, Van-Riet I, Van-Camp B, Thielemans K (1994) Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. Br J Haematol 87: 68-74
5. Bergsagel PL, Chesi M, Nardini E, Brents LA, Kirby SL, Kuehl WM (1996) Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci USA 93: 13931-13935
6. Billadeau D, Jelinek DE, Shah N, LeBien TW, Van Ness B (1995) Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin-6 dependent myeloma cell line ANBL6. Cancer Res 55: 3640-3646
7. Calasanz MJ, Cigudosa JC, Odero MD, Ferreira C, Ardanaz MT, Fraile A, Carrasco JL, Sole F, Braulia C, Gullon A (1997) Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations. Genes Chromosomes Cancer 18: 84-93
8. Chang H, Bouman D, Boerkoel CF, Stewart AK, Squire JA (1999) Frequent monoallelic loss of D13S319 in multiple myeloma patients shown by interphase fluorescence in situ hybridization. Leukemia 13: 105-109
9. Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM, Bergsagel PL (1997) Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma: association with increased expression and activating mutations of fibroblast growth factor receptor 3. Nature Genet 16: 260-265
10. Chesi M, Bergsagel PL, Shonukan OO, Martelli ML, Brents LA, Chen T, Schroeck E, Ried T, Kuehl WM (1998) Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 91: 4457-4462
11. Cigudosa JC, Rao PH, Calasanz MJ, Odero MD, Michaeli J, Jhanwar SC, Chaganti RSK (1998) Characterization of nonrandom chromosomal gains and losses in multiple myeloma by comparative genomic hybridization (CGH). Blood 91: 3007-3013
12. Corradini P, Bocadoro M, Voena C, Pileri A (1993a) Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to Cμ sequence in immunoglobulin (IgG)-and IgA-secreting multiple myelomas. J Exp Med 178: 1091-1096
13. Corradini P, Ladetto M, Voena C, Palumbo A, Inghirami G, Knowles DM, Boccadoro M, Pileri A (1993b) Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. Blood 81: 2708-2715
14. Dao D, Sawyer J, Epstein J, Hoover R, Barlogie B, Tricot G (1994) Deletion of the retinoblastoma gene in multiple myeloma. Leukemia 8: 1280-1284
15. Dewald GW, Kyle RA, Hicks GA, Greipp PR (1985) The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 66: 380-390
16. Drach J, Schuster J, Nowotny H, Angerler J, Rosenthal F, Fiegl M, Rothermundt C, Gsur A, Jaeger U, Heinz R, Lechner K, Ludwig H, Huber H (1995a) Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Res 55: 3854-3859
17. Drach J, Angerler J, Schuster J, Rothermundt C, Thalhammer R, Haas OA, Jaeger U, Fiegl M, Geissler K, Ludwig H, Huber H (1995b) Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood 86: 3915-3921
18. Drach J, Ackermann J, Fritz E, Kroemer E, Schuster R, Gisslinger H, DeSantis M, Zojer N, Fiegl M, Roka S, Schuster J, Heinz R, Ludwig H, Huber H (1998) Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional dose chemotherapy. Blood 92: 802-807
19. Flactif M, Zandecki M, Lai JL, Bernardi F, Obein V, Bauters F, Facon T (1995) Interphase fluorescence in situ hybridization (FISH) as a powerful tool for the detection of aneuploidy in multiple myeloma. Leukemia 9: 2109-2114
20. Fonseca R, Aguayo P, Ahmann GJ, Jalal SM, Rajkumar SV, Kyle RA, Gertz MA, Dewald GW, Dispenzieri A, Lust JA, Lacy MQ, Witzig TE, Greipp PR (1999) Translocations at 14q32 are common in patients with monoclonal gammopathy of undetermined significance. Blood 94 [Suppl 1]: 663a
21. Gazitt Y, Reading CC, Hoffman R, Wickrema A, Vesole DH, Jagannath S, Condino J, Lee B, Barlogie B, Tricot G (1995) Purified CD34+Lin-Thy+ stem cells do not contain clonal myeloma cells. Blood 86: 381-389
22. Gould J, Alexanian R, Goodacre A, Pathak S, Hecht B, Barlogie B (1988) Plasma cell karyotypes in multiple myeloma. Blood 71: 453-456
23. Grell R, Fasching B, Loidl P, Huber H (1991) Expression of the c-myc proto-oncogene in multiple myeloma and chronic lymphocytic leukemia: an in situ analysis. Blood 78: 180-187
24. Hallek M, Bergsagel PL, Anderson KC (1998) Multiple myeloma: increasing evidence for a multistep transformation process. Blood 91: 3-21
25. Ho F, Lortan J, Khan M, MacLennan ICM (1986) Distinct short-lived and long-lived antibody producing cell populations. Eur J Immunol 16: 1297-1301
26. Iida S, Butler M, Rao P, Corradini P, Boccadoro M, Klein B, Chaganti RSK, Dalla-Favera R (1997) Deregulation of MUM1/IRF4 by chromosomal translocations in multiple myeloma. Nat Genet 17: 226-231
27. Juge-Morineau N, Mellerin M-P, Francois S, Rapp M-J, Harousseau JL, Amiot M, Bataille R (1995) High incidence of deletions but infrequent inactivation of the retinoblastoma gene in human myeloma cells. Br J Haematol 91: 664-668
28. Klein B (1995) Cytokines, cytokine receptors, transduction signals, and oncogenes in human multiple myeloma. Semin Hematol 32: 4-19
29. Königsberg R, Ackermann J, Zojer N, Kaufmann H, Gisslinger H, Krömer E, Heinz R, Schuster J, Ludwig H, Huber H, Drach J (1999) Interphase fluorescence in situ hybridization reveals presence of 13q14 deletions in plasma cells from patients with monoclonal gammopathy of undetermined significance (MGUS). Blood 94 [Suppl 1]: 541a
30. Königsberg R, Zojer N, Ackermann J, Krömer E, Kittler H, Fritz E, Kaufmann H, Nösslinger T, Riedl L, Gisslinger H, Jäger U, Simonitsch I, Heinz R, Ludwig H, Huber H, Drach J (2000) Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol 18: 804-812
31. Kuehl WM, Chesi M, Brents LA, Huppi K, Bergsagel PL (1997) Dysregulation of c-myc in multiple myeloma. Curr Topics Microbiol Immunol 224: 277-290
32. Lai JL, Zandecki M, Mary JY, Bernardi F, Izydorczyk V, Flactif M, Morel P, Jouet JP, Bauters F, Facon T (1995) Improved cytogenetics in multiple myeloma - a study of 151 patients including 117 patients at diagnosis. Blood 85: 2490-2497
33. Liu PC, Leong T, Quam L, Billadeau D, Kay NE, Greipp P, Kyle RA, Oken MM, Van Ness B (1996) Activating mutations of N- and K-ras in multiple myeloma show different clinical associations - analysis of the Eastern Cooperative Oncology Group phase III trial. Blood 88: 2699-2706
34. Neri A, Murphy JP, Cro L, Ferrero D, Tarella C, Baldini L, Dalla-Favera R (1989) ras oncogene mutation in multiple myeloma. J Exp Med 170: 1715-1722
35. Neri A, Baldini L, Trecca D, Cro L, Polli E, Maiolo AT (1993) p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 81: 128-133
36. Nishida K, Tamura A, Nakazawa N, Ueda Y, Abe T, Matsuda F, Kashima K, Taniwaki M (1997) The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood 90: 526-534
37. Paquette RL, Berenson J, Lichtenstein A, McCormick F, Koeffler HP (1990) Oncogenes in multiple myeloma: point mutations of N-ras. Oncogene 5: 1659-1705
38. Perez-Simon JA, Garcia-Sanz R, Tabernero MD, Almeida J, Gonzalez M, Fernandez-Calvo J, Moro MJ, Hernandez JM, San Miguel JF, Orfao A (1998) Prognostic value of numerical chromosome aberrations in multiple myeloma: a FISH analysis of 15 different chromosomes. Blood 91: 3366-3371
39. Portier M, Moles J-P, Mazars G-R, Jeanteur P, Bataille R, Klein B, Theillet C (1992) p53 and RAS gene mutations in multiple myeloma. Oncogene 7: 2539-2545
40. Rao PH, Cigudosa JC, Ning Y, Calasanz MJ, Iida S, Tagawa S, Michaeli J, Klein B, Dalla-Favera R, Jhanwar SC, Ried T, Chaganti RSK (1998) Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma. Blood 92: 1743-1748
41. Rasmussen T, Jensen L, Honore L, Andersen H, Johnsen HE (1999) Circulating clonal cells in multiple myeloma do not express CD34 mRNA, as measured by single-cell and real-time RT-PCR assays. Br J Haematol 107: 818-824
42. Rettig MB, Ma HJ, Vescio RA, Fold M, Schiller G, Belson D, Savage A, Nishikubo C, Wu C, Fraser J, Said JW, Berenson JR (1997) Kaposi's sarcoma-associated herpes virus infection of bone marrow dendritic cells from multiple myeloma patients. Science 276: 1851-1854
43. Richelda R, Ronchetti D, Baldini L, Cro L, Viggiano L, Marzella R, Rocchi M, Otsuki T, Lombardi L, Maiolo AT, Neri A (1997) A novel chromosomal translocation t(4;14)(p16.3;q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood 90: 4062-4069
44. Ronchetti D, Finelli P, Richeldi R, Baldini L, Rocchi M, Viggiano L, Cuneo A, Bogni S, Fabris S, Lombardi L, Maiolo A, Neri A (1999) Molecular analysis of 11q13 breakpoints in multiple myeloma. Blood 93: 1330-1337
45. Sawyer JR, Waldron JA, Jagannath S, Barlogie B (1995) Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 82: 41-49
46. Sawyer J, Tricot G, Mattox S, Jagannath S, Barlogie B (1998a) Translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of heterochromatin. Blood 91: 1732-1741
47. Sawyer JR, Lukacs JL, Munshi N, Desikan KR, Singhai S, Mehta J, Siegel D, Shaughnessy J, Barlogie B (1998b) Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping. Blood 92: 4269-4276
48. Schreiber S, Ackermann J, Obermair A, Fuchs K, Kaufmann H, Urbauer E, Gisslinger H, Chott A, Huber H, Drach J (2000) Multiple myeloma with deletion of chromosome 13q is characterised by increased bone marrow neovascularisation. (Submitted for publication)
49. Selvanayagam P, Blick M, Narni F, van Tuinen P, Ledbetter DH, Alexanian R, Saunders GF, Barlogie B (1988) Alteration and abnormal expression of the c-myc oncogene in human multiple myeloma. Blood 71: 30-35
50. Seong C, Delasalle K, Hayes K, Weber D, Dimopoulos M, Swantkowski J, Huh Y, Glassman A, Champlin R, Alexanian R (1998) Prognostic value of cytogenetics in multiple myeloma. Br J Haematol 101: 189-194
51. Shaughnessy J, Tian E, Bell T, Xiao Y, Spoon D, Butch A, Drach J, Sawyer J, Barlogie B (1998) Molecular cytogenetic analysis of chromosome 13q14, site of a putative tumor suppressor gene in multiple myeloma. Blood 92 [Suppl 1]: 259a
52. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeldis J, Barlogie B (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341: 1565-1571
53. Szczepek AJ, Bergsagel PL, Axelsson L, Brown CB, Belch AR, Pilarski LM (1997) CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ gene rearrangements. Blood 89: 1824-1833
54. Tarte K, Chang Y, Klein B (1999) Kaposi's sarcoma-associated herpes virus and multiple myeloma: lack of criteria for causality. Blood 93: 3159-3163
55. Tew JG, DiLosa RM, Burton GF, Kosco MH, Kupp LI, Masuda A, Szakal AK (1992) Germinal centers and antibody production in bone marrow. Immunol Rev 126: 99-112
56. Treon SP, Shima Y, Raje N, Tai YT, Hideshima T, Chauhan D, Grossbard ML, Preffer FI, Doss D, Schlossman R, Szczepek AJ, Belch AR, Pilarski LM, Anderson KC (1999) Interferon-γ induces CD20 expression on multiple myeloma cells via induction of Pu.1 and augments rituximab binding to myeloma cells. Blood 94 [Suppl 1]: 119a
57. Tricot G, Sawyer J, Jagannath S, Bracy D, Mattox S, Vesole D, Naucke S, Barlogie B (1995) Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 86: 4250-4256
58. Vacca A, Ribatti D, Roncali L, Dammacco F (1995) Angiogenesis in B cell lymphoproliferative diseases: biological and clinical studies. Leuk Lymphoma 20: 27-38
59. Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R, Albini A, Bussolino F, Dammacco F (1999) Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93: 3064-3073
60. Vescio RA, Hong CH, Cao J, Kim A, Schiller GJ, Lichtenstein AK, Berenson RJ, Berenson JR (1994) The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma. Blood 84: 3283-3290
61. Weh HJ, Gutensohn K, Selbach J, Kruse R, Wacker-Backhaus G, Seeger B, Fiedler W, Fett W, Hossfeld DK (1993) Karyotype in multiple myeloma and plasma cell leukemia. Eur J Cancer 29A: 1269-1273
62. Zandecki M, Obein V, Bernardi F, Soenen V, Flactif M, Lai JL, Francois M, Facon T (1995) Monoclonal gammopathy of undetermined significance: chromosome changes are a common finding within bone marrow plasma cells. Br J Haematol 90: 693-696
63. Zandecki M, Lai JL, Facon T (1996) Multiple myeloma: almost all patients are cytogenetically abnormal. Br J Haematol 94: 217-223
64. Zojer N, Königsberg R, Ackermann J, Fritz E, Dallinger S, Krömer E, Kaufmann H, Riedl L, Gisslinger H, Schreiber S, Heinz R, Ludwig H, Huber H, Drach J (2000) In multiple myeloma, deletion of 13q14 remains an independent adverse prognostic parameter despite its frequent detection by interphase FISH. Blood 95: 1925-1930